Blockage of the RAS significantly inhibits the expression of PAI-1 in the liver [15], and angiotensin receptor blockers (ARB), a class of medications that antagonize the angiotensin receptor and suppress RAS, have been proposed as a novel treatment for NAFLD in part not only because they decrease PAI-1 but also because they improve insulin resistance [16]. The gene discussed is SERPINE1; the disease is metabolic dysfunction-associated steatotic liver disease.